Check-Cap (NASDAQ:CHEK) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Check-Cap (NASDAQ:CHEK) in a report released on Saturday. The firm issued a sell rating on the medical research company’s stock.

Check-Cap Price Performance

CHEK stock opened at $0.92 on Friday. The business has a 50 day simple moving average of $1.47 and a 200-day simple moving average of $1.87. The firm has a market capitalization of $5.39 million, a PE ratio of -0.28 and a beta of 0.39. Check-Cap has a 1 year low of $0.80 and a 1 year high of $3.85.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.